nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
|
Azambuja, Evandro de |
|
2009 |
4 |
2 |
p. 77-88 |
artikel |
2 |
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors
|
Snider, Kelly L. |
|
2009 |
4 |
2 |
p. 67-76 |
artikel |
3 |
Indexing: the north face
|
Morère, Jean-François |
|
2009 |
4 |
2 |
p. 63 |
artikel |
4 |
Maximum tolerated dose: clinical endpoint for a bygone era?
|
Takimoto, Chris H. |
|
2009 |
4 |
2 |
p. 143-147 |
artikel |
5 |
QT interval prolongation among patients treated with angiogenesis inhibitors
|
Ederhy, Stephane |
|
2009 |
4 |
2 |
p. 89-97 |
artikel |
6 |
Renal toxicity of targeted therapies
|
Kelly, Ronan J. |
|
2009 |
4 |
2 |
p. 121-133 |
artikel |
7 |
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors
|
Kelly, Kevin |
|
2009 |
4 |
2 |
p. 99-105 |
artikel |
8 |
Skin toxicities associated with epidermal growth factor receptor inhibitors
|
Li, Tianhong |
|
2009 |
4 |
2 |
p. 107-119 |
artikel |
9 |
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents
|
Sankhala, Kamalesh |
|
2009 |
4 |
2 |
p. 135-142 |
artikel |
10 |
The toxicities of modern targeted therapies—learning from the price of progress
|
Giles, Francis J. |
|
2009 |
4 |
2 |
p. 65-66 |
artikel |